CENP-B - 0.2mg

CENP-B - 0.2mg

Regular price
$693.82
Regular price
Sale price
$693.82
Unit price
per 
Availability
Sold out

Major centromere autoantigen B
Centromere protein B

Uniprot ID:  P07199
mRNA RefSeq:  NM_001810
Protein RefSeq:  NP_001801
Size: 0.2mg
Source: Recombinant
Catalogue Number: ATC02-02

Product Information

Autoantibodies to centromeric proteins in the sera of patients with scleroderma were first described in 1980. Subsequent studies confirmed that anti-centromere antibodies (ACA) were most often found in patients with a limited form of systemic sclerosis previously referred to as CREST syndrome. These autoantibodies are also often detected in sera from patients with Raynaud’s phenomenon and occasionally in other rheumatic diseases such as systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis.  ACA have also been reported to occur with high prevalence in patients with primary biliary cirrhosis, in patients with malignancies and occasionally in normal individuals.

Although at least 9 proteins are known to be associated with the centromere complex, CENP-B is normally considered to be the major centromere antigen, since autoantibodies to this protein were found to be present at high titres in all ACA sera while titres of antibodies directed at two other centromere antigens (CENP-A, CENP-C) were often much lower. CENP-B is a dimer composed of two 80-kDa subunits which binds specifically to the 17bp CENP-B box sequence that is required for the formation of a functional centromere and is located within chromosomal α-satellite DNA . CENP-B may therefore function as a trans-acting factor that regulates the formation or centromere-specific chromatin on the α-satellite DNA repeat at the nucleosome assembly level.

Autoantibodies have been reported to bind to at least 3 different epitope regions of CENP B however the 60 amino acid C-terminal region appears to constitute the major autoimmune epitope.
 

PDF-logo-dl CENP-Bdatasheet

Clinical Indications

Systemic Sclerosis (CREST syndrome)
Systemic Lupus Erythematosus
Sjögren’s syndrome
Rheumatoid Arthritis
Primary Biliary Cirrhosis

MSDS

PDF-logo-dl  Material Safety Data Sheet

References

Moroi, Y. et al. (1980) Proc. Natl. Acad. Sci. USA 77, 1627

Tan, E.M. et al. (1980) Arthritis Rheum. 23, 617

McCarty, G.A. et al. (1983) Arthritis Rheum. 26, 1

Chorzelski, T.P. et al. (1985). Br. J. Dermatol. 113, 381

Miller, M.H. et al. (1987) Br. J. Rheumatol. 26, 17

Chan, H.L. et al. (1994) Clin. Exp. Dermatol. 19, 298

Zuber, M. et al. (1994) Clin. Rheumatol. 13, 427

Caramaschi, P. et al. (1995) Rheumatol. Int. 14, 253

Russo, K. et al. (2000) J. Rheumatol. 27, 142

Miyawaki, S. et al. (2005) J. Rheumatol. 32, 1488

Parveen, (1995) J. Gastroenterol. Hepatol. 10, 438

Abu-Shakra, M. et al. (2001) Ann. Rheum. Dis. 60, 433

Atalay, C. et al. (2005) Neoplasma 52, 32

Briasoulis, E. et al. (2008) Lung Cancer in press

Lee, S.L. et al. (1993) Annals Rheum. Dis. 52, 586

Reveille, J.D. et al. (2003) Arthritis Rheum. 49, 399

Earnshaw, W. et al. (1986) J. Clin. Invest. 77, 426

Earnshaw, W. et al. (1987) J. Cell Biol. 104, 817

Kitagawa, K. et al. (1995) Mol. Cell Biol. 15, 1602

Tanaka, Y. et al. (2005). J. Biol. Chem. 280, 41609

Verheijen, R. (1994) Man. Biol. Markers Dis.(Kluwer Acad. Publ.) B2/1-17v

Earnshaw, W.et al. (1987) Proc. Natl. Acad. Sci. USA 84, 4979

Rothfield, N. et al. (1987) Arthritis Rheum. 30, 1416

Verheijen, R. (1992) Mol. Biol. Reports 16, 49Stahnke, G. (1994) J. Autoimmun. 7, 107